Product image of Insuman Comb 25 Solostar (Insulin Human) supplied by GNH India

Insuman Comb 25 Solostar

Active Ingredient:
Insulin Human
Origin:
EU

Insuman Comb 25 Solostar (Insulin Human)

Insulin human, the active ingredient in Insuman Comb 25 Solostar, is an insulin presented as a premixed insulin injection solution for subcutaneous use. It lowers blood glucose in patients with type 1 and type 2 diabetes mellitus by replacing deficient endogenous insulin.

GNH India supplies Insuman Comb 25 Solostar as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies, clinics and other healthcare institutions worldwide. The company adheres to stringent quality standards and provides regulatory documentation to support import and distribution across multiple regions.

Manufacturer / TM Owner

Sanofi-Aventis Deutschland Gmbh

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

  • Insuman Comb 25 Solostar is an antidiabetic insulin preparation used to manage blood glucose in diabetes mellitus.
  • Type 1 diabetes mellitus: provides rapid‑acting and intermediate‑acting insulin to achieve basal‑prandial glucose control.
  • Type 2 diabetes mellitus: supplies combined insulin action to improve overall glycemic control in patients requiring insulin therapy.
  • Diabetes mellitus requiring intensified insulin regimen: offers a convenient premixed formulation to simplify multiple daily injections.

How It Works

  • Insulin human binds to insulin receptors on muscle, adipose and hepatic cells, activating the receptor tyrosine kinase pathway. This triggers translocation of GLUT‑4 transporters to the cell membrane, enhancing glucose uptake, and suppresses hepatic gluconeogenesis, thereby lowering circulating blood glucose. The premixed formulation contains both rapid‑acting and intermediate‑acting components, delivering immediate post‑prandial coverage and sustained basal insulin effect.

Side Effects

Insuman Comb 25 Solostar may be associated with a range of adverse reactions following subcutaneous administration.

Common Side Effects

  • Hypoglycemia: low blood glucose episodes.
  • Injection site reactions: pain, redness or swelling at the injection site.
  • Weight gain: increase in body weight during therapy.

Serious or Rare Side Effects

  • Severe hypoglycemia: loss of consciousness or seizures.
  • Allergic reactions: anaphylaxis, urticaria or angioedema.
  • Lipodystrophy: abnormal fat accumulation or loss at injection sites.

Precautions & Warnings

  • When using Insuman Comb 25 Solostar, several precautions should be observed to ensure safe and effective therapy.
  • Dose adjustment: modify dose based on blood glucose monitoring and clinical response.
  • Renal impairment: monitor closely as insulin clearance may be reduced.
  • Hepatic dysfunction: assess glucose control regularly.
  • Concurrent illness: increase monitoring during infection or stress.
  • Pregnancy and lactation: use only if benefits outweigh risks.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Insuman Comb 25 Solostar can interact with other medicines, altering its glucose‑lowering effect or increasing risk of adverse events.

Major Interactions (Avoid)

  • Beta‑blockers: may mask hypoglycemia symptoms.
  • MAO inhibitors: can potentiate insulin effect.
  • Systemic corticosteroids: may cause hyperglycemia requiring dose increase.

Moderate Interactions (Monitor Closely)

  • Thiazide diuretics: may raise blood glucose.
  • Oral antidiabetic agents (e.g., sulfonylureas): additive hypoglycemia risk.
  • ACE inhibitors: may enhance insulin sensitivity.

Frequently Asked Questions

Insuman Comb 25 Solostar is a premixed insulin preparation indicated for the treatment of type 1 and type 2 diabetes mellitus. It provides both rapid‑acting and intermediate‑acting insulin to help patients achieve better glycaemic control when oral agents are insufficient.

Insulin human mimics the action of natural human insulin by binding to insulin receptors on muscle, fat and liver cells. This activates intracellular pathways that promote glucose uptake, inhibit hepatic glucose production, and facilitate storage of nutrients, thereby lowering blood glucose levels.

The dose of Insuman Comb 25 Solostar is individualized. A qualified prescriber determines the total daily units, the timing of injections, and any dose adjustments based on the patient’s blood‑glucose monitoring, lifestyle, and clinical response.

Safety data for insulin human in pregnancy and lactation are limited. It may be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and only under close medical supervision.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Insuman Comb 25 Solostar contains human insulin in a 1:1 ratio of rapid‑acting to intermediate‑acting components, similar to other premixed products such as NovoMix or Humulin 30. Differences lie in the specific insulin source, concentration, and approved regional indications, but all aim to simplify basal‑prandial coverage with fewer injections.

The product must be stored refrigerated at 2‑8 °C, protected from light, and must not be frozen or shaken. Once in use, the vial can be kept at room temperature for up to 28 days, but any unused solution should be discarded after that period.

Insuman Comb 25 Solostar is given by subcutaneous injection, typically into the abdomen, thigh or upper arm. The injection should be performed using a sterile needle, rotating sites to avoid lipodystrophy, and following the prescriber’s dosing schedule.

The most serious risks include severe hypoglycaemia, which can cause loss of consciousness or seizures, and allergic reactions such as anaphylaxis or angio‑edema. Patients should be educated to recognise early signs and seek immediate medical attention if they occur.

Insuman Comb 25 Solostar is contraindicated in individuals with a known hypersensitivity to human insulin or any excipients in the formulation. Caution is also advised for patients with severe renal or hepatic impairment, as dose adjustments may be required.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Insulin Human

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT